Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nifedipine
Drug ID BADD_D01566
Description Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
Indications and Usage Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.[L11383] Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.[L11389,L1245]
Marketing Status approved
ATC Code C08CA05
DrugBank ID DB01115
KEGG ID D00437
MeSH ID D009543
PubChem ID 4485
TTD Drug ID D04OSE
NDC Product Code 0904-7229; 46438-0635; 52932-0711; 0069-2670; 68981-039; 23155-194; 23155-195; 43826-031; 46708-732; 50090-1843; 50742-622; 51655-738; 55289-798; 62332-734; 68084-597; 68382-687; 68645-512; 68682-106; 70771-1365; 71335-0497; 48589-0006; 51927-0233; 0069-2660; 46708-734; 50742-261; 50742-262; 51407-624; 0228-2497; 60429-049; 62175-262; 62332-732; 68084-598; 70771-1192; 71610-055; 11014-0036; 11014-0341; 52133-0028; 60592-507; 50742-260; 59651-297; 68071-2619; 68382-688; 68645-603; 68682-108; 69315-211; 70771-1191; 70807-503; 71335-0744; 71335-1721; 71335-9651; 55154-4690; 68084-603; 70934-973; 11014-0035; 11014-0342; 48292-0034; 62991-1106; 43826-030; 46708-733; 50268-598; 50742-621; 51655-780; 55154-4157; 62175-261; 63629-9109; 68382-686; 68682-105; 70771-1366; 71610-689; 0904-7081; 0069-2650; 24979-009; 24979-011; 50268-599; 50742-620; 59651-295; 59651-296; 59762-1004; 67877-757; 68645-513; 68682-109; 71205-965; 71335-0489; 71610-290; 72162-1277; 38779-0280; 51927-5205; 65427-250; 71052-650; 51655-407; 51655-798; 60429-048; 62135-521; 67877-758; 68382-689; 70934-603; 71205-963; 71335-2132; 71610-144; 72214-503; 72789-219; 49452-4847; 52133-0009; 24979-010; 50268-597; 51655-386; 62135-523; 62175-260; 62332-733; 68382-685; 71205-412; 71335-1550; 71610-012; 0904-7082; 82920-709; 43826-032; 0228-2530; 53808-1118; 62135-522; 63187-875; 68682-107; 68788-7642; 68788-8164; 69315-212; 70518-2679; 70518-3520; 12527-0787; 0904-7208; 46438-0052; 60524-002; 50090-4158; 50090-5284; 50090-5328; 50090-6201; 50090-6450; 51655-990; 55154-8177; 67877-756; 68071-4411; 68382-690; 68645-604; 70771-1190; 70771-1367; 70934-963; 71205-964; 11014-0038; 51552-0720; 50090-4234; 50090-6203; 51407-622; 51407-623; 51655-593; 60429-047
UNII I9ZF7L6G2L
Synonyms Nifedipine | Bay-1040 | Bay 1040 | Bay1040 | BAY-a-1040 | BAY a 1040 | BAYa1040 | Cordipin | Cordipine | Corinfar | Korinfar | Nifangin | Nifedipine Monohydrochloride | Monohydrochloride, Nifedipine | Procardia | Procardia XL | Nifedipine-GTIS | Nifedipine GTIS | Vascard | Adalat | Fenigidin
Chemical Information
Molecular Formula C17H18N2O6
CAS Registry Number 21829-25-4
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.000567%
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.0010.000112%Not Available
Acidosis14.01.03.0020.000075%
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000112%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.000224%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.0040.000075%Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000075%Not Available
Amblyopia06.02.01.001--Not Available
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.004--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000187%Not Available
Anuria20.01.03.0020.000075%Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.0010.000075%Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000075%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.000254%
Arthropathy15.01.01.003--Not Available
Ascites02.05.04.002; 09.01.05.003; 07.07.01.0010.000075%
Asthenia08.01.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene